Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Iron overload is a well-known critical issue in transfusion dependent patients affected by chronic hematological diseases, as thalassemic syndromes (TS)1ormyelodisplastic syndromes (MDS)2.Excess iron can be extremely toxic may cause organ damage in the absence of iron chelation therapy. Preclinical studies on the role of free iron toxicity on bone marrow function have shown that this condition leads to an accumulation of reactive oxygen species, interfers with the expression of genes encoding for hematopoiesis regulating proteins, and inhibits hematopoiesis.

Source: Leukemia Research - December 4, 2018 Category: Hematology Authors: Ambra Di Veroli, Alessia Campagna, Marianna De Muro, Malgorzata Monika Trawinska, Sabrina LeonettiCrescenzi, Luca Petriccione, Atelda Romano, Ada D ’Addosio, Antonia Cenfra, Marco Montanaro, Stefano Felici, Alessandro Andriani, Ida Carmosino, Pasquale N Tags: Research paper Source Type: research